The epidemiological landscape of lung cancer: current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022
Background: Given the relatively unfavorable prognosis and significant geographic differences in lung cancer burden, it is critical to update the global landscape of lung cancer to inform local strategies. Methods: Based on the GLOBOCAN 2022, the age-standardized incidence rate (ASIR) and mortality...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Journal of the National Cancer Center |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667005425000201 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849423673659752448 |
|---|---|
| author | Yuting Ji Yunmeng Zhang Siwen Liu Jingjing Li Qianyun Jin Jie Wu Hongyuan Duan Xiaomin Liu Lei Yang Yubei Huang |
| author_facet | Yuting Ji Yunmeng Zhang Siwen Liu Jingjing Li Qianyun Jin Jie Wu Hongyuan Duan Xiaomin Liu Lei Yang Yubei Huang |
| author_sort | Yuting Ji |
| collection | DOAJ |
| description | Background: Given the relatively unfavorable prognosis and significant geographic differences in lung cancer burden, it is critical to update the global landscape of lung cancer to inform local strategies. Methods: Based on the GLOBOCAN 2022, the age-standardized incidence rate (ASIR) and mortality rate (ASMR) were compared and linked to the Human Development Index (HDI) across different populations. The temporal trends in ASIR/ASMR were characterized as estimated annual percentage change (EAPC), and demographic projections were performed up to 2050. Results: Globally, an estimated 2,480,675 cases and 1,817,469 deaths from lung cancer occurred in 2022. Both ASIR and ASMR of lung cancer varied widely by world region, with ASIR ranging from 2.06 to 39.38 per 100,000 and ASMR from 1.95 to 31.70 per 100,000. China alone accounted for >40 % of cases and deaths worldwide. Both ASIR and ARMR of lung cancer increased with HDI (R2: 0.54 and 0.47, all P values <0.001), regardless of gender. Based on available data, both ASIR during 2001–2010 and ASMR during 2001–2015 showed decreasing trends in males (EAPC: 1.50 % and −2.22 %) but increasing trends in females (EAPC: 1.08 % and 0.07 %). Similar trends in ASIR and ASMR were observed among the elder population (≥50 years); however, downward trends were observed in the younger population (<50 years). Alongside the aging and growth of the population, estimated cases and deaths from overall lung cancer would increase by 86.2 % and 95.2 % up to 2050 as compared with estimates in 2022, respectively. Notably, increased early-onset lung cancer was only observed in transitioning countries, while decreased early-onset lung cancer was observed in transitioned countries. Conclusion: Lung cancer maintained as the leading cancer burden worldwide. Unless timely preventive interventions in tobacco mitigation, early screening, and precise treatment, the global lung cancer burden is expected to increase in the future, especially for transitioning countries. |
| format | Article |
| id | doaj-art-875366eeebc14f5c9276052f432be50d |
| institution | Kabale University |
| issn | 2667-0054 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the National Cancer Center |
| spelling | doaj-art-875366eeebc14f5c9276052f432be50d2025-08-20T03:30:32ZengElsevierJournal of the National Cancer Center2667-00542025-06-015327828610.1016/j.jncc.2025.01.003The epidemiological landscape of lung cancer: current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022Yuting Ji0Yunmeng Zhang1Siwen Liu2Jingjing Li3Qianyun Jin4Jie Wu5Hongyuan Duan6Xiaomin Liu7Lei Yang8Yubei Huang9Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Tianjin, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Tianjin, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Tianjin, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Tianjin, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Tianjin, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Tianjin, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Tianjin, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Tianjin, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaPeking University Cancer Hospital (Inner Mongolia Campus)/Affiliated Cancer Hospital of Inner Mongolia Medical University, Inner Mongolia Cancer Center, Hohhot, China; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital & Institute, Beijing, China; Corresponding authors.Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Tianjin, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China; Corresponding authors.Background: Given the relatively unfavorable prognosis and significant geographic differences in lung cancer burden, it is critical to update the global landscape of lung cancer to inform local strategies. Methods: Based on the GLOBOCAN 2022, the age-standardized incidence rate (ASIR) and mortality rate (ASMR) were compared and linked to the Human Development Index (HDI) across different populations. The temporal trends in ASIR/ASMR were characterized as estimated annual percentage change (EAPC), and demographic projections were performed up to 2050. Results: Globally, an estimated 2,480,675 cases and 1,817,469 deaths from lung cancer occurred in 2022. Both ASIR and ASMR of lung cancer varied widely by world region, with ASIR ranging from 2.06 to 39.38 per 100,000 and ASMR from 1.95 to 31.70 per 100,000. China alone accounted for >40 % of cases and deaths worldwide. Both ASIR and ARMR of lung cancer increased with HDI (R2: 0.54 and 0.47, all P values <0.001), regardless of gender. Based on available data, both ASIR during 2001–2010 and ASMR during 2001–2015 showed decreasing trends in males (EAPC: 1.50 % and −2.22 %) but increasing trends in females (EAPC: 1.08 % and 0.07 %). Similar trends in ASIR and ASMR were observed among the elder population (≥50 years); however, downward trends were observed in the younger population (<50 years). Alongside the aging and growth of the population, estimated cases and deaths from overall lung cancer would increase by 86.2 % and 95.2 % up to 2050 as compared with estimates in 2022, respectively. Notably, increased early-onset lung cancer was only observed in transitioning countries, while decreased early-onset lung cancer was observed in transitioned countries. Conclusion: Lung cancer maintained as the leading cancer burden worldwide. Unless timely preventive interventions in tobacco mitigation, early screening, and precise treatment, the global lung cancer burden is expected to increase in the future, especially for transitioning countries.http://www.sciencedirect.com/science/article/pii/S2667005425000201Lung cancerincidencemortalitytemporal trendHDI |
| spellingShingle | Yuting Ji Yunmeng Zhang Siwen Liu Jingjing Li Qianyun Jin Jie Wu Hongyuan Duan Xiaomin Liu Lei Yang Yubei Huang The epidemiological landscape of lung cancer: current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022 Journal of the National Cancer Center Lung cancer incidence mortality temporal trend HDI |
| title | The epidemiological landscape of lung cancer: current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022 |
| title_full | The epidemiological landscape of lung cancer: current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022 |
| title_fullStr | The epidemiological landscape of lung cancer: current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022 |
| title_full_unstemmed | The epidemiological landscape of lung cancer: current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022 |
| title_short | The epidemiological landscape of lung cancer: current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022 |
| title_sort | epidemiological landscape of lung cancer current status temporal trend and future projections based on the latest estimates from globocan 2022 |
| topic | Lung cancer incidence mortality temporal trend HDI |
| url | http://www.sciencedirect.com/science/article/pii/S2667005425000201 |
| work_keys_str_mv | AT yutingji theepidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT yunmengzhang theepidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT siwenliu theepidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT jingjingli theepidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT qianyunjin theepidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT jiewu theepidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT hongyuanduan theepidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT xiaominliu theepidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT leiyang theepidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT yubeihuang theepidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT yutingji epidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT yunmengzhang epidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT siwenliu epidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT jingjingli epidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT qianyunjin epidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT jiewu epidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT hongyuanduan epidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT xiaominliu epidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT leiyang epidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 AT yubeihuang epidemiologicallandscapeoflungcancercurrentstatustemporaltrendandfutureprojectionsbasedonthelatestestimatesfromglobocan2022 |